^
Association details:
| Biomarker: | MET overexpression |
|---|---|
| Cancer: | Adrenal Cortex Carcinoma |
| Drug: | Cometriq (cabozantinib capsule) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Hepatocyte growth factor/cMET pathway activation enhances cancer hallmarks in adrenocortical carcinoma
Excerpt:
...Bioinformatics analysis revealed marked overexpression of oncogenes while down-regulation of tumor suppressor genes in association with high expression of MET...in vivo inhibition of cMET by cabozantinib...significantly (P<0.001) reduced tumor growth…ACC tumor growth is dependent, at least in part, on cMET signaling, and cMET inhibition is likely to have a role in treatment of advanced ACC...
DOI:
10.1158/0008-5472.CAN-14-3707
